An Assessment of CAR-T Cell Therapy Utilization among Racial and Ethnic Minority Patients

LaQuisa C Hill¹, Melody Smith^{2

3}

Affiliations

¹ Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, Houston.
² Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA.
³ Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA.

Editorial

LaQuisa C Hill et al. NEJM Evid. 2024 Apr.

. 2024 Apr;3(4):EVIDe2400022.

doi: 10.1056/EVIDe2400022. Epub 2024 Mar 26.

LaQuisa C Hill¹, Melody Smith^{2

3}

¹ Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, Houston.
² Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA.
³ Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA.

No abstract available

Comment on

CAR T-Cell Immunotherapy in Minority Patients with Lymphoma.
Ghilardi G, Williamson S, Pajarillo R, Paruzzo L, Chen L, Grady C, Doucette A, Nemecek E, Gabrielli G, Barta SK, Svoboda J, Chong EA, Yelton R, Nasta SD, Landsburg DJ, Ugwuanyi O, Chen AI, Schachter L, White G, Ballard HJ, Weber E, Curley C, Porter DL, Garfall AL, Hwang WT, Guerra CE, Maziarz RT, Schuster SJ, Ruella M. Ghilardi G, et al. NEJM Evid. 2024 Apr;3(4):EVIDoa2300213. doi: 10.1056/EVIDoa2300213. Epub 2024 Mar 26. NEJM Evid. 2024. PMID: 38776868